Table 5.
Cost-effectiveness analysis results according to PFS and OS for each treatment group. Amounts are presented in MXN pesos
| TKI | Mean total cost | Incremental Cost | Effectiveness | Incremental Effectiveness | ICER |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | |||||
| Gefitinib | $161,800 | 8.18 | Lowest cost | ||
| Erlotinib | $215,700 | $53,900 | 6.7 | −1.48 | Dominated by gefitinib |
| Afatinib | $348,200 | $186,400 | 9.46 | 1.28 | $145,625.00 vs gefitinib |
| Overall Survival (OS) | |||||
| Gefitinib | $161,800 | 27.1 | Lowest cost | ||
| Erlotinib | $215,700 | $53,900 | 21.7 | −5.4 | Dominated by gefitinib |
| Afatinib | $348,200 | $186,400 | 37.1 | 10 | $18,640.00 vs gefitinib |